{
    "clinical_study": {
        "@rank": "90759", 
        "arm_group": {
            "arm_group_label": "Single arm", 
            "arm_group_type": "Other", 
            "description": "Single arm trial"
        }, 
        "brief_summary": {
            "textblock": "This study will be a single subject study to evaluate the efficacy of the HER2 kinase\n      inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene\n      fusion."
        }, 
        "brief_title": "Single Subject Neratinib in Bladder Cancer", 
        "completion_date": {
            "#text": "July 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        * none\n\n        Exclusion Criteria:\n\n        * none\n\n        We have received FDA approval for a single subject Investigational New Drug (IND)\n        Application to treat a specific patient with the HER2 kinase inhibitor neratinib.\n        Therefore there is no inclusion / exclusion criteria."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956253", 
            "org_study_id": "13-2526"
        }, 
        "intervention": {
            "arm_group_label": "Single arm", 
            "description": "240 mg orally once daily", 
            "intervention_name": "Neratinib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bladder Cancer", 
            "Neratinib", 
            "13-2526"
        ], 
        "lastchanged_date": "October 4, 2013", 
        "link": {
            "description": "Lineberger Comprehensive Cancer Center", 
            "url": "http://cancer.med.unc.edu/"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Chapel Hill", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27599"
                }, 
                "name": "North Carolina Cancer Hospital (UNC)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Single Subject Neratinib in Bladder Cancer", 
        "overall_official": {
            "affiliation": "UNC Lineberger Comprehensive Cancer Center", 
            "last_name": "William Kim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the response of a single subject with metastatic bladder cancer to Neratinib.  Efficacy will be assessed by using Response Evaluation Criteria in Solid Tumors (RECIST 1.1).", 
            "measure": "Response", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956253"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "UNC Lineberger Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UNC Lineberger Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}